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Abstract
Introduction Gene expression profiling has been successfully
used to classify breast cancer into clinically distinct subtypes,
and to predict the risk of recurrence and treatment response.
The aim of this study was to investigate whether the gene
expression profile (GEP) detected in a core biopsy (CB) is
representative for the entire tumor, since CB is an important tool
in breast cancer diagnosis. Moreover, we investigated whether
performing CBs prior to the surgical excision could influence the
GEP of the respective tumor.
Methods We quantified the RNA expression of 60 relevant
genes by quantitative real-time PCR in paired CBs and surgical
specimens from 22 untreated primary breast cancer patients.
Subsequently, expression data were compared with
independent GEPs obtained from tumors of 317 patients
without preceding CB.
Results In 82% of the cases the GEP detected in the CB
correlated very well with the corresponding profile in the surgical
sample (rs ≥ 0.95, p < 0.001). Gene-by-gene analysis revealed
four genes significantly elevated in the surgical sample
compared to the CB; these comprised genes mainly involved in
inflammation and the wound repair process as well as in tumor
invasion and metastasis.
Conclusion A GEP detected in a CB are representative for the
entire tumor and is, therefore, of clinical relevance. The observed
alterations of individual genes after performance of CB deserve
attention since they might impact the clinical interpretation with
respect to prognosis and therapy prediction of the GEP as
detected in the surgical specimen following CB performance.
Introduction
Gene expression profiling by parallel detection of thousands of
genes permits the molecular signature (phenotype) of a tissue
sample to be read and can, therefore, individually characterize
a patient's tumor at the molecular level. Based on the gene
expression profile (GEP) of a tumor, a molecular classification
for breast cancer was proposed [1] and several molecular sig-
natures were reported to predict the risk of recurrence and
treatment response [2-5]. Such molecular analyses require
only small amounts of material, such as tissue samples
obtained by minimal invasive methods, for example, core
biopsy (CB), which are used to assess the nature of palpable
and non-palpable breast lesions to confirm or exclude the
diagnosis of breast cancer [6-9].
Although CB investigations have become more and more
important in the early workup of breast lesions, there are only
a few investigations regarding the reliability of GEPs as
detected in CBs [10]. However, wound healing subsequent to
CB can potentially induce gene expression alterations in the
injured tissue. Many of these normally occurring reparative
CB = core biopsy; COX = cyclooxygenase; Ct = cycle threshold; GEP = gene expression profile; MMP = matrix metalloproteinase; qrt-PCR = quan-
titative real-time PCR; PAI = plasminogen activator inhibitor; PAI-1 = Plasminogen Activator Inhibitor-1; ST = surgical tumor tissue specimen; uPAR 
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processes share molecular characteristics with an aggressive
cancer phenotype, such as cell proliferation and survival, ang-
iogenesis, and extracellular matrix remodeling; these biological
hallmarks were shown to predict the clinical course in cancer
[3,11-13]. Therefore, potential biological changes induced by
CB require further study since they may have important conse-
quences for clinical outcome prediction and treatment deci-
sions as well as the interpretation of GEP changes
investigated in neo-adjuvant studies.
We explored the molecular expression levels of 60 genes
using quantitative real-time PCR (qrt-PCR), a highly sensitive
and reproducible method, in paired CB and surgical samples.
These genes were selected according to their known links to
malignant cell behavior in breast cancer and their importance
in major cancer hallmarks, such as proliferation, survival, inva-
siveness and angiogenic potential, and in the wound healing
process [14]. Our first objective was to investigate whether
the molecular profile of a CB is representative for the whole
tumor. The second objective was to study if the repair process
following CB alters the GEP and if this is influenced by the
timeframe between the CB and the surgical excision.
Table 1
Clinicopathological characteristics and gene expression variation of each patient
Difference in gene expression between 
CB and ST (∆Ct [GeneST] – ∆Ct 
[GeneCB])
Patient 
number
Age Time between 
CB and ST 
(days)
Histology Tumor 
diameter 
(cm)
Grade Lymph node 
involvement
Correlation (rs) 
between 
paired CB and 
ST
PAI-1 COX-2 ERBB2
1 68 7 Ductal 3.3 3 Negative 0.97 -0.39 -0.15 -0.08
2 59 8 Ductal 1.8 3 Negative 0.98 -1.68 -0.20 0.52
3 49 21 Ductal 3.3 2 Positive 0.98 -1.19 -1.03 0.62
4 57 13 Ductal 1.1 1 Positive 0.89 -0.63 0.61 -0.02
5 63 14 Ductal 9.0 2 Negative 0.97 -1.41 -1.80 1.40
6 60 21 Ductulo-
lobular
2.7 1 Positive 0.98 -1.38 -2.41 0.23
7 80 12 Ductal 3.1 1 Positive 0.95 -2.62 -1.39 0.44
8 81 14 Lobular 2.8 2 Positive 0.94 -3.78 -3.73 0.29
9 34 14 Ductal 1.8 2 Negative 0.95 -3.16 -1.37 0.12
10 68 10 Ductal 0.9 2 Micrometastasis 0.87 -3.57 -7.27 1.01
11 65 16 Lobular 1.9 1 Negative 0.89 -5.16 -0.80 -0.02
12 80 13 Ductal 6.0 3 Positive 0.86 -2.16 -0.20 0.63
13 59 2 Apocrine 2.7 3 Negative 0.98 -1.18 -4.64 -0.27
14 73 12 Lobular 1.9 2 Positive 0.95 -4.60 -3.97 -1.85
15 61 1 Lobular 2.3 2 Positive 0.89 -1.88 -1.61 -0.94
16 73 22 Ductal 1.9 2 Negative 0.98 -1.28 -0.34 0.26
17 58 3 Ductal 9.0 2 Positive 0.96 -0.48 0.26 -0.42
19 68 13 Ductal 1.2 1 Negative 0.97 -2.18 -2.62 0.31
18a 67 11 Ductal 1.5 2 Micrometastasis NA NA NA NA
20 44 13 Ductulo-
lobular
3.2 3 Positive 0.98 -0.12 0.01 0.19
21 71 20 Ductulo-
lobular
1.7 3 Negative 0.95 -3.15 -1.69 0.26
22 53 5 Ductal 1.3 2 Negative 0.92 -2.81 -5.48 -0.08
aRNA in the core biopsy (CB) of this patient was degraded and, therefore, omitted from the study. COX, cyclooxygenase; NA, not available; PAI-1, 
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Materials and methods
Tumor specimen acquisition
Between June 2004 and June 2005, 22 consecutive breast
cancer patients entered this study, for which both CBs and
surgical tumor tissue specimens (STs) were available. This
study was undertaken at the Women's University Hospital
Basel, Switzerland, and approved by the local institutional
review board (EKBB permission Nr. 81/04). Written informed
consent was obtained from all patients.
All CBs (14-gauge needle, Magnum® Core high speed, Bard
Medica, Karlsruhe, Germany) were obtained under sono-
graphic guidance (HDI 5'000 Sono CT®, Philips, Zurich, Swit-
zerland) under local anesthesia through a skin incision in a
sterile field. Five biopsy specimens were taken routinely for
each patient. Two biopsy specimens were divided longitudi-
nally; two halves to be used for molecular examination were,
within one minute, stored in RNAlater®-solution (Qiagen,
Basel, Switzerland), while the other two halves as well as the
other three biopsies were immediately put in formaldehyde
and sent for histological examination to the Institute of Pathol-
ogy, University Hospital Basel.
After establishing the diagnosis of breast cancer, all patients
underwent breast surgery with sentinel node lymphonodec-
tomy or axillary lymphonodectomy if indicated. All surgical
samples were examined by the same pathologist. If the tumor
tissue was larger than 0.5 cm in diameter at the intra-operative
frozen section, a representative piece containing more than
60% tumor cells was cryopreserved within five minutes and
made available to the Stiftung Tumorbank Basel for molecular
examination. The rest of the tumor tissue was embedded in
paraffin for routine histological examination.
Reference study population
RNA expression levels of all 60 genes were detected using the
same qrt-PCR method in 317 surgically excised breast cancer
specimens [15] from patients undergoing primary surgery in
1992 to 1996 without previous examination by CB. All tissue
samples were prepared by the pathologists as described
above, all samples contained more than 60% tumor cells and
Figure 1
Unsupervised hierarchical clustering of paired core biopsy and surgical tumor tissue samples (Spearman correlation, average linkage) Unsupervised hierarchical clustering of paired core biopsy and surgical tumor tissue samples (Spearman correlation, average linkage). Red color 
indicates high expression levels (low ∆Ct) and green vice versa. Patients 6, 11 and 20 had two core biopsies taken that were analyzed separately. In 
four cases the paired gene expression profiles did not cluster together close to each other.Breast Cancer Research    Vol 8 No 4    Zanetti-Dällenbach et al.
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they were cryoperserved within five minutes. The Stiftung
Tumorbank Basel was subsequently responsible for collec-
tion, storage at -70°C and analysis.
RNA extraction and qrt-PCR
Detailed procedures have been published elsewhere [16]. In
brief, RNA was extracted using the RNeasy Mini Kit (Qiagen,
Inc., Valencia, CA, USA), quantified and quality-checked on a
Bioanalyzer 2100 (RNA 6000 Nano LabChip-Kit, Agilent
Technologies, New Castle, DE, USA). High quality RNA sam-
ples were reverse-transcribed (10 mM DDT, 1 µg of hexamer
primers, 2 U of MMLV Reverse Transcriptase (Invitrogen,
Basel, Switzerland), 40 U of RNasin (Promega, Wallisellen,
Switzerland), 0.5 mM of each dNTP (Promega), 1× reaction
buffer). PCR primers were designed to be cDNA specific and
ordered at GeneScan Europe (Freiburg, Germany). PCR was
performed in 40 cycles on an ABI Prism 7000 using 2× SYBR
Green I Master Mix (Applied Biosystems, Forster City, CA,
USA) in a final volume of 25 µl. Relative quantities (∆Ct) were
obtained by normalization against ribosomal 18S RNA, and
standardization was achieved with Human Universal Standard
RNA (Stratagene Europe, Amsterdam, The Netherlands). The
60 genes quantitatively assessed are listed in Table 1.
Statistical analysis
The same amount of RNA was used for the GEP analysis of
each sample. For statistical analysis, ∆Ct expression values of
each gene were obtained by normalizing the raw gene values
to 18S rRNA as a reference gene.
Cluster and TreeView programs were used to perform unsu-
pervised hierarchical clustering of samples and genes (Spear-
man correlation, average linkage) [17]. Spearman correlation
coefficients were calculated to compare the GEPs of all paired
samples. Differentially expressed genes were identified with
the paired two-sample t-test. The Mann-Whitney U-test was
used to compare median expression values of genes among
different subgroups of patients. All statistical analyses were
carried out at 5% level of significance and performed with S-
Plus software (Version 6.1, Insightful Corporation, Seattle,
WA, USA).
Results
Patient characteristics
The mean age of the 22 patients was 63 years (range: 34 to
81 years). The period between CB and final surgery ranged
from 1 to 23 days. The mean tumor diameter was 2.9 cm
(range: 0.9 to 9 cm). Clinicopathological characteristics of
each patient are listed in Table 1. Of note, one paired tissue
sample was not further evaluated due to poor RNA quality, and
RNA extracted from the two halves of the CB was not pooled
in three cases but analyzed separately.
Comparison of the gene expression profile in paired 
samples
As shown in Figure 1, unsupervised hierarchical clustering
revealed that paired CB and ST generally clustered together;
in only four cases (patients 4, 10, 11, and 12) did the GEP of
the CB not agglomerate with the profile of the respective ST.
Interestingly, the two separate CBs taken from patient 11 were
very similar to each other, although they differed from their ST
GEP. The gene dendrogram of the cluster analysis also
revealed that samples agglomerated in two main groups
according to their respective estrogen receptor status, recon-
firming the representative value of this study population.
Subsequent analysis of paired CBs and STs confirmed the
high correlation between all samples (rs from 0.86 to 0.98, all
p < 0.001) for each patient. A scatter plot of two representa-
tive examples of a paired CB/ST is displayed in Figure 2. The
differences in paired GEPs does not seem to be related to the
Figure 2
Correlation between the gene expression profiles (60 genes) of paired core biopsies (CB) and surgical tumor tissue specimens (ST) Correlation between the gene expression profiles (60 genes) of paired core biopsies (CB) and surgical tumor tissue specimens (ST). (a) Specimens 
from patient 2 (rs = 0.98), as representative for 82% of all cases. (b) Specimens from patient 12, as representative for less correlated paired gene 
expression profiles (rs = 0.86).Available online http://breast-cancer-research.com/content/8/4/R51
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timeframe between CB and surgery or to any other clinico-
pathological parameters (Table 1).
Gene-by-gene analysis in core biopsies and paired 
surgical specimens
The comparison of the expression levels of individual genes by
means of paired t-test showed no significant difference
between CB and ST with the exception of four genes. Plas-
minogen activator inhibitor 1 (PAI-1; also known as
SERPINE1) was significantly higher expressed (lower ∆Ct val-
ues) in STs compared to CBs (p < 0.001, Table 1). Similar dif-
ferences, although less pronounced, were observed for
cyclooxygenase 2 (COX-2; also known as PTGS2; p <
0.001), urokinase plasminogen activator receptor (uPAR; also
known as PLAUR; p = 0.003) and matrix metalloproteinase 1
(MMP1; p = 0.03). The increase in the expression of these
genes was not related to the timeframe between CB and sur-
gery. All other genes were very similarly expressed in paired
CB/ST as shown in Figure 3. Table 1 lists differences in RNA
expression values of PAI-1, COX-2 and ERBB2 for paired
samples of each patient.
Histological re-examination of cryocuts of the surgical speci-
mens revealed a certain amount of inflammation and fibrolysis.
Whether these observations are due to cancerogenesis or to
a de novo induced wound repair process can not be deter-
mined.
Comparison of the expression levels of selected genes 
with a reference study population of surgical tumor 
tissue specimens
To verify whether the higher expression levels of PAI-1 and
COX-2 observed in STs could have been induced by the pre-
ceding CB procedure, we compared the expression levels of
the same genes in an independent population of 317 primary
breast cancer patients. These samples were investigated with
the same qrt-PCR technique but were from patients from
which no CB had been taken prior to surgery. As shown in Fig-
ure 4, the expression levels of PAI-1 and COX-2 measured in
the independent STs without CB were found to be very similar
to the levels detected in CBs and significantly different from
those detected in STs after CB. Moreover, no variation at all
Figure 3
Box plots displaying the changes in the expression of each gene in the surgical specimens (ST) compared to the respective core biopsies (CB) Box plots displaying the changes in the expression of each gene in the surgical specimens (ST) compared to the respective core biopsies (CB).Breast Cancer Research    Vol 8 No 4    Zanetti-Dällenbach et al.
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was observed for the remaining genes as illustrated by the
expression levels of ERBB2 as an example.
Discussion
Ultrasound-guided CB is a well established method to diag-
nose breast cancer in women, since it is a reliable, and time-
and cost-saving method. The clinical utility of the information
gained by CB depends on whether the CB is representative
for the whole tumor. Our data demonstrate that the quantita-
tive expression levels of 60 genes detected in CBs were highly
comparable to their paired STs in 17 out of the 21 cases inves-
tigated. Even in the cases where GEPs of a CB and ST did not
agglomerate, the expression levels of the ER and progester-
one receptor as well as ERBB2 measured in the CB were also
representative for the whole tumor. This is important since
today's therapy decisions are based on these markers
obtained either by CB or ST (St Gallen consensus recommen-
dations [18]). In addition, our results reconfirm previous obser-
vations reported by immunohistochemistry [19,20] or semi-
qrt-PCR [21].
Tissue sampling by CB causes a local injury, inducing wound
healing that is characterized by recruitment of inflammatory
cells, stimulation of stromal and epithelial cell proliferation, cell
migration and increased angiogenesis. Analysis on a gene-by-
gene basis demonstrated higher expression levels of PAI-1,
COX-2, uPAR and MMP1 in STs compared to their paired
CBs, whereas no changes were observed for all other genes.
These results are not surprising since proteinases (such as
PAI-1 and uPAR) are known to be essentially involved in the
wound healing process [22,23] and COX-2 plays roles in
inflammation and angiogenesis [24-27].
However, many of these reparation processes show parallels
with cancerogenesis [28-30]; while proteinases, their inhibi-
tors, cyto-/chemokines and growth factors are essential for
wound healing and tissue repair, they also play central roles in
cancer progression. For example, uPA, uPAR and its inhibitor
PAI-1 are responsible for the degradation and remodeling of
the extracellular matrix, and are further involved in angiogen-
esis, cell adhesion and migration necessary for tumor cell inva-
sion and metastasis [31,32]. COX-2 can be induced by
cytokines and growth factors during the inflammatory repair
process as well as in cancer [24-26,30] resulting in COX-2
overexpression observed in human malignancies [25-27].
Therefore, increased levels of these markers in the tumor
specimen could suggest a more aggressive cancer pheno-
type. Indeed, elevated levels of uPA and PAI-1 are associated
with poor clinical outcome in breast cancer and also have pre-
dictive value [33-35]. Moreover, a previously identified
'wound-response signature' turned out to be prognostic in
several carcinomas, including breast cancer [12,13]. Although
COX-2 has been associated with increased Vascular
Endothelial Growth Factor A (VEGF), estrogen synthesis, pro-
liferation, apoptosis and invasion [25,27,36], in our study,
higher levels of COX-2 were not accompanied by changes in
the expression of genes involved in these processes, indicat-
ing that the observed molecular alterations influence data
interpretation but not tumor aggressiveness.
Conclusion
Our study demonstrates that expression levels of ER, proges-
terone receptor, ERBB2 and other genes relevant for the man-
agement of breast cancer as detected in CBs are
representative for the whole tumor. However, increased
expression levels of proteinases (e.g. PAI-1, uPAR, MMP1)
Figure 4
Notch box plots of the expression levels of plasminogen activator inhibitor (PAI)-1, cyclooxygenase (COX)-2 and HER-2 as detected Notch box plots of the expression levels of plasminogen activator inhibitor (PAI)-1, cyclooxygenase (COX)-2 and HER-2 as detected (a) in 317 inde-
pendent surgical specimens of primary breast cancer patients who did not undergo previous diagnosis by core biopsy, (b) in the core biopsy of the 
21 patients entering this study, and (c) in the corresponding surgical excisions.Available online http://breast-cancer-research.com/content/8/4/R51
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and COX-2 in STs compared to their paired CBs suggest
induction of theses genes during the repair process following
tissue injury caused by CBs. This observation is important
since such molecular alterations may have an impact on the
clinical interpretation of GEPs detected in STs with respect to
the prediction of risk assessment and treatment response.
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